Diane Levitan left the role of Director at PetVivo Holdings, Inc., effective September 22, 2026. As of November 6, 2026, PetVivo Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 22, 2026 to September 22, 2026, naming 2 appointments and 2 departures (Form 8-K, September 22, 2026).
PetVivo Holdings, Inc. named a new Director on Sep 22. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like PetVivo Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
PetVivo Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-22 to 2026-09-22. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as PetVivo Holdings, Inc. files it.
Also on the record for PetVivo Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 15, 2026 | Stake report, Schedule 13D/A, by A.L. Sarroff Fund, LLC | 38.2% of the class | 5%+ stakes | Source |
| August 5, 2026 | Stake report, Schedule 13G, by Alexander Nazarenko | 18.73% of the class | 5%+ stakes | Source |
| March 13, 2026 | Stake report, Schedule 13D/A, by A.L. Sarroff Fund, LLC | 39.6% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13G/A, by CRUDEN STANLEY C | 9.4% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13D, by A.L. Sarroff Fund, LLC | 36.1% of the class | 5%+ stakes | Source |
| October 31, 2025 | Stake report, Schedule 13G/A, by A.L. Sarroff Fund, LLC | 31.7% of the class | 5%+ stakes | Source |
| October 14, 2025 | Stake report, Schedule 13G/A, by CRUDEN STANLEY C | 9.8% of the class | 5%+ stakes | Source |
| July 28, 2025 | Stake report, Schedule 13G/A, by CRUDEN STANLEY C | 10% of the class | 5%+ stakes | Source |
| July 10, 2025 | Stake report, Schedule 13G/A, by A.L. Sarroff Fund, LLC | 29.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs PetVivo Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on PetVivo Holdings, Inc. and the records around it.
PetVivo Holdings, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
Watch PetVivo Holdings, Inc.
Get an email when PetVivo Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on PetVivo Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on PetVivo Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PetVivo Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-22 | Out | Director | 2026-09-22 | 8-K, 2026-09-22 | |
| 2026-09-22 | In | Director | 2026-09-22 | 8-K, 2026-09-22 | |
| 2026-09-22 | Out | Director | 2026-09-22 | 8-K, 2026-09-22 | |
| 2026-09-22 | In | Director | 2026-09-22 | 8-K, 2026-09-22 |
Who leads PetVivo Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Diane Levitan, departure reported, effective 2026-09-22 (filed 2026-09-22). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on PetVivo Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at PetVivo Holdings, Inc., with the record behind each one.
Find candidates like Director at PetVivo Holdings, Inc.Every change, in the filing's words
Departing: Diane Levitan, Director, effective 2026-09-22
Effective September 22, 2026, Diane Levitan resigned as a member of the Board of Directors (the "Board") of PetVivo Holdings, Inc., a Nevada corporation (the "Company").
Appointed: Jaime K. Pickett, Director, effective 2026-09-22
Appointment of Jaime K. Pickett Effective September 22, 2026, the Board appointed Jaime K. Pickett as a director of the Company to fill the vacancy created by Dr. Levitan's resignation, thereby maintaining the size of the Board at six directors.
- Dr. Levitan's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Board expresses its appreciation to Dr. Levitan for her leadership, guidance and contributions during her tenure on the Board.
- Dr. Pickett will serve until the next annual meeting of shareholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.
- Dr. Pickett is a veterinary healthcare executive, entrepreneur, multi-unit franchisee and board leader with more than 20 years of experience spanning animal health, multi-site operations, corporate strategy, business development, clinical innovation, product commercialization and organizational growth.
- She currently serves as Chief Medical Officer of EQUUSIR USA and as Advising Chief Medical Officer and a board member of Alexander International Innovations, where she provides clinical, regulatory, commercialization and strategic guidance for emerging medical and animal-health technologies.
- She also serves on the Board of Chief Veterinary Medical Officers, a professional organization of senior veterinary executives, and is a Scenthound multi-unit franchisee.
Departing: Joseph Jasper, Director, effective 2026-09-22
Effective September 22, 2026, Joseph Jasper resigned as a member of the Board of Directors (the "Board") of PetVivo Holdings, Inc., a Nevada corporation (the "Company").
Appointed: Michael K. Handley, Director, effective 2026-09-22
Appointment of Michael K. Handley Effective September 22, 2026, the Board appointed Michael K. Handley as a director of the Company to fill the vacancy created by Mr. Jasper's resignation, thereby maintaining the size of the Board at six directors.
- Mr. Jasper's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Board expresses its appreciation to Mr. Jasper for his leadership, guidance and contributions during his tenure on the Board.
- Mr. Handley will serve until the next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
- Mr. Handley is a life sciences executive and board director with more than 25 years of experience in the biotechnology, pharmaceutical and medical device industries.
- He has raised more than $700 million in public and private capital, supported more than 80 global product launches, and led or contributed to transactions with an aggregate value exceeding $4 billion.
- His experience includes corporate strategy and governance, capital markets, investor relations, mergers and acquisitions, licensing, clinical development, regulatory affairs, commercialization and global operations.
- Mr. Handley served as Chief Executive Officer and a director of Valion Bio, Inc. from March to August 2026 and as its Chief Operating Officer and President of Statera Biopharma from February 2025 to March 2026.
Tools for this story
Each opens in a new tab, filled in for PetVivo Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.